These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21157066)

  • 1. Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360° synechial angle-closure glaucoma: a preliminary study.
    Vyas P; Naik U; Gangaiah JB
    Indian J Ophthalmol; 2011; 59(1):13-6. PubMed ID: 21157066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of latanoprost and bimatoprost on intraocular pressure in chronic angle-closure glaucoma.
    Chen MJ; Chen YC; Chou CK; Hsu WM
    J Ocul Pharmacol Ther; 2007 Dec; 23(6):559-66. PubMed ID: 18001247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 12-week, double-masked, parallel-group study of the safety and efficacy of travoprost 0.004% compared with pilocarpine 1% in Chinese patients with primary angle-closure and primary angle-closure glaucoma.
    Wu LL; Huang P; Gao YX; Wang ZX; Li B
    J Glaucoma; 2011 Aug; 20(6):388-91. PubMed ID: 21336155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-week study evaluating the efficacy of bimatoprost 0.03% in patients with pseudoexfoliative and open-angle glaucoma.
    Ciancaglini M; Carpineto P; Agnifili L; Nubile M; Toto L; Mastropasqua L
    Eur J Ophthalmol; 2009; 19(4):594-600. PubMed ID: 19551674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma.
    Martinez A; Sanchez M
    Curr Med Res Opin; 2007 May; 23(5):1025-32. PubMed ID: 17519068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of bimatoprost monotherapy in primary chronic angle closure and primary open angle glaucoma eyes: a three-year study.
    Gupta V; Srinivasan G; Sharma A; Kapoor KS; Sihota R
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):351-8. PubMed ID: 17803433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma.
    How AC; Kumar RS; Chen YM; Su DH; Gao H; Oen FT; Ho CL; Seah SK; Aung T
    Br J Ophthalmol; 2009 Jun; 93(6):782-6. PubMed ID: 19336424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, prospective study of bimatoprost 0.01% or travoprost/timolol in patients previously treated with latanoprost and timolol to reduce intraocular pressure.
    Nixon DR
    J Ocul Pharmacol Ther; 2013 Dec; 29(10):876-81. PubMed ID: 24070367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.
    Wang K; Xu L; Yuan Z; Yao K; Zhao J; Xu L; Fang A; Zhang M; Wu L; Ji J; Hou J; Liu Q; Sun X
    BMC Ophthalmol; 2014 Feb; 14():21. PubMed ID: 24568617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension.
    Katsanos A; Dastiridou AI; Fanariotis M; Kotoula M; Tsironi EE
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):67-71. PubMed ID: 21214361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intraocular pressure-lowering effect of every night versus every other night dosing of bimatoprost 0.03%.
    Shazly TA; Latina MA
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):369-71. PubMed ID: 21663517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost.
    Sonty S; Donthamsetti V; Vangipuram G; Ahmad A
    J Ocul Pharmacol Ther; 2008 Oct; 24(5):517-20. PubMed ID: 18800869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
    Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
    Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of intraocular pressure lowering efficacy of bimatoprost / timolol fixed combination and other glaucoma medications in the treatment of glaucoma].
    Skorkovská K
    Cesk Slov Oftalmol; 2008 Jul; 64(4):144-8. PubMed ID: 18780653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma.
    Konstas AG; Holló G; Mikropoulos D; Tsironi S; Haidich AB; Embeslidis T; Georgiadou I; Irkec M; Melamed S
    Br J Ophthalmol; 2010 Feb; 94(2):209-13. PubMed ID: 19825835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma.
    Sato S; Hirooka K; Baba T; Mizote M; Fujimura T; Tenkumo K; Ueda H; Shiraga F
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):499-502. PubMed ID: 21790301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure.
    Sherwood M; Brandt J;
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S361-8. PubMed ID: 11434939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
    Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT
    Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension.
    Katz LJ; Cohen JS; Batoosingh AL; Felix C; Shu V; Schiffman RM
    Am J Ophthalmol; 2010 Apr; 149(4):661-671.e1. PubMed ID: 20346780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.